Add-on activity
This activity includes a patient perspective.
Program Description
Cystic fibrosis (CF) is a burdensome inherited disease in which a thick mucus forms over the respiratory, reproductive, and digestive systems. Common among the White population, CF occurs in 1 of every 2000 to 4000 live births, totaling over 30,000 patients in the United States, and costs nearly $131,000 per patient. With no current cure for CF, multifaceted symptomatic treatments and prophylactic regimens have improved survival and tolerability of the disease. CF transmembrane conductance regulator (CFTR) modulators are a medication class that address the basic deficit in CF and include potentiators, which open the CFTR channel function, and correctors, which assist in the transport of CFTR to the cell surface. Pharmacists are essential in helping patients navigate through the complex treatment regimens with capabilities of monitoring drug-drug interactions, ensuring appropriate dosing, and providing patient education. This activity will provide pharmacists with critical knowledge of CF and its treatment challenges, emerging therapies, as well as strategies to improve the outcomes of patients. Integrated within the program is a patient perspective interview that highlights the experience of a patient living with CF and how the patient navigated diagnosis and treatment.
Target audience: Health-system, retail, and specialty pharmacists
Type of activity: Application
Release date: September 13, 2022
Expiration date: November 13, 2022
Time to complete activity: 1.5 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Explain the pathophysiology, clinical burden, and treatment challenges in cystic fibrosis (CF)
- Examine the efficacy and safety of current and emerging therapies, including CF transmembrane conductance regulator modulators
- Analyze patient and provider barriers that impact optimal treatment of patients with CF
- Employ strategies to individualize patient care and improve outcomes
David Young, PharmD
Clinical Professor
Clinical Pharmacist
Department of Pharmacotherapy
University of Utah Adult Cystic Fibrosis & Asthma Centers
Residency Director
PGY-2 Internal Medicine Pharmacy
Salt Lake City, Utah
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-350-L01-P. The activity is available for CE credit through November 13, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
David Young, PharmD, has the following relevant financial relationships with commercial interests to disclose:
Grant/Research Support: Cystic Fibrosis Foundation
Consultant: Lexicomp
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Abigail Dill; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms